Fund focus: Genesis targets China's tech inflection points
With $850 million in dry powder to deploy from its second US dollar-denominated fund, China’s Genesis Capital is targeting Series C and D rounds for start-ups on the cusp of greatness
Genesis Capital’s sweet spot is defined by timing, as well as by industry and size: the Chinese growth-stage investor wants to back technology-enabled companies after their products are proven but before...
More on Greater China
Latest News
Bain targets $102m Japan advertising take-private
Bain Capital has won board approval from Net Marketing, a Tokyo-listed online advertising and media management business, for a take-private that values the company at approximately JPY 13.6bn (USD 102m).
China's Insilico Medicine gets another $35m
Insilico Medicine, a China-based artificial intelligence-driven drug discovery company, has closed the second tranche of its Series D round on USD 35m, with Prosperity7 Ventures taking the lead.
Singapore crypto risk platform extends Series A to $24m
Singapore’s Merkle Science, a predictive crypto analytics platform, has raised USD 24m in Series A funding led by K3 Ventures, Darrow Holdings, and Beco Capital.
Cartesian seals deal for China rollout of restaurant chain Popeyes
Cartesian Capital Group, a US private equity firm that has served as Restaurant Brands International’s (RBI) joint venture partner for Burger King in China for the past decade, has been awarded exclusive country development rights for the company’s...